Skip to Content

Provectus Biopharmaceuticals Inc PVCT

Morningstar Rating
$0.15 0.00 (0.90%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PVCT is trading at a 40% discount.
Price
$0.14
Fair Value
$5.85
Uncertainty
Extreme
1-Star Price
$7.00
5-Star Price
$4.71
Economic Moat
Dtny
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PVCT is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.14
Day Range
$0.140.15
52-Week Range
$0.060.17
Bid/Ask
$0.14 / $0.15
Market Cap
$60.83 Mil
Volume/Avg
203,938 / 223,688

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Provectus Biopharmaceuticals Inc is a is a clinical-stage biotechnology company. It is engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The company has developed and intends to license or market and sell its two prescription drug candidates, PV-10 and PH-10. Its PV-10 is for the treatment of several life-threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The PH-10 is to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
4

Valuation

Metric
PVCT
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
PVCT
Quick Ratio
0.04
Current Ratio
0.17
Interest Coverage
−14.40
Quick Ratio
PVCT

Profitability

Metric
PVCT
Return on Assets (Normalized)
−172.47%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
PVCT
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRVcnz$546.8 Bil
VRTX
Vertex Pharmaceuticals IncBdkxzzr$112.0 Bil
REGN
Regeneron Pharmaceuticals IncMmhbw$108.6 Bil
MRNA
Moderna IncLzcx$35.9 Bil
ARGX
argenx SE ADRZnr$24.1 Bil
BNTX
BioNTech SE ADRBlbty$22.2 Bil
ALNY
Alnylam Pharmaceuticals IncXlkrvv$20.0 Bil
BMRN
Biomarin Pharmaceutical IncMyzyn$17.0 Bil
RPRX
Royalty Pharma PLC Class AWnhtxd$14.0 Bil
INCY
Incyte CorpStvkpw$13.6 Bil

Sponsor Center